SEC, FDA sign three-year agreement on disclosures and information-sharing

By Atlas Watchline Staff · Regulatory · August 31, 2026

The Securities and Exchange Commission and the Food and Drug Administration said they have signed a three-year memorandum to expand cooperation on market oversight, disclosure issues and public health matters.

The Securities and Exchange Commission and the Food and Drug Administration said Monday they entered into a three-year memorandum of understanding to strengthen cooperation, information-sharing and oversight tied to FDA-related disclosures.

The agencies said the agreement is meant to support the SEC’s mission of protecting investors and maintaining fair markets, and the FDA’s role in protecting public health. It sets a framework for coordination on regulatory and enforcement responsibilities.

The MOU also includes information-sharing protocols so the two agencies can exchange material relevant to both of their missions, according to the SEC’s announcement.

The agencies said the arrangement is intended to help them respond to issues that can affect public companies, investors, patients and regulated products. The SEC said FDA-related disclosures by public companies can have a significant impact on markets.

In a statement, SEC Chairman Paul S. Atkins said the FDA is a partner in administering and enforcing disclosure requirements under federal securities laws. He said FDA-related disclosures by public companies affect markets.

Acting FDA Commissioner Kyle Diamantras, J.D., said the partnership aims to enhance transparency across the life sciences sector. He said streamlining information-sharing helps protect patients who rely on FDA-regulated products and the public trust that supports healthcare innovation.

The memorandum remains in effect for three years. The agencies said it may be extended or modified by mutual written consent.

Sources

• SEC press release

Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.

This is the AMP version of the article. Read the full article on Atlas Watchline.